JP2003526686A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526686A5
JP2003526686A5 JP2001566747A JP2001566747A JP2003526686A5 JP 2003526686 A5 JP2003526686 A5 JP 2003526686A5 JP 2001566747 A JP2001566747 A JP 2001566747A JP 2001566747 A JP2001566747 A JP 2001566747A JP 2003526686 A5 JP2003526686 A5 JP 2003526686A5
Authority
JP
Japan
Prior art keywords
amino
phenylamino
carbonitrile
cyano
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001566747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003526686A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/007068 external-priority patent/WO2001068186A2/en
Publication of JP2003526686A publication Critical patent/JP2003526686A/ja
Publication of JP2003526686A5 publication Critical patent/JP2003526686A5/ja
Withdrawn legal-status Critical Current

Links

JP2001566747A 2000-03-13 2001-03-06 結腸ポリープの治療または阻害するためのシアノキノリンの使用 Withdrawn JP2003526686A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13
US09/524,196 2000-03-13
PCT/US2001/007068 WO2001068186A2 (en) 2000-03-13 2001-03-06 Use of cyanoquinolines for treating or inhibiting colonic polyps

Publications (2)

Publication Number Publication Date
JP2003526686A JP2003526686A (ja) 2003-09-09
JP2003526686A5 true JP2003526686A5 (https=) 2008-04-24

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001566747A Withdrawn JP2003526686A (ja) 2000-03-13 2001-03-06 結腸ポリープの治療または阻害するためのシアノキノリンの使用

Country Status (23)

Country Link
EP (1) EP1263503B1 (https=)
JP (1) JP2003526686A (https=)
KR (2) KR100817423B1 (https=)
CN (1) CN1190197C (https=)
AR (1) AR035482A1 (https=)
AT (1) ATE308364T1 (https=)
AU (2) AU2001245452B2 (https=)
BR (1) BR0109165A (https=)
CA (1) CA2402742C (https=)
DE (1) DE60114580T2 (https=)
DK (1) DK1263503T3 (https=)
EA (1) EA200200976A1 (https=)
ES (1) ES2248302T3 (https=)
HK (1) HK1048775B (https=)
HU (1) HUP0300547A2 (https=)
IL (2) IL151249A0 (https=)
MX (1) MXPA02008836A (https=)
NO (1) NO20024356L (https=)
NZ (1) NZ521117A (https=)
PL (1) PL202873B1 (https=)
TW (1) TWI262805B (https=)
WO (1) WO2001068186A2 (https=)
ZA (1) ZA200208178B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2003064399A1 (fr) * 2002-01-28 2003-08-07 Ube Industries, Ltd. Procede de production de derive de quinazolin-4-one
BR0307375A (pt) * 2002-02-05 2004-12-07 Wyeth Corp Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−3阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
JP2007537230A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006127203A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Znf143阻害活性を有する化合物およびその利用
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2026017799A1 (en) * 2024-07-18 2026-01-22 Centre Hospitalier Universitaire Vaudois Substituted 3-cyanoquinolines for the prevention and treatment of sexually transmitted diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
HUP0203162A3 (en) * 1999-08-12 2006-07-28 Wyeth Holdings Corp Madison Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Similar Documents

Publication Publication Date Title
JP2003526686A5 (https=)
ZA200208178B (en) Use of cyanoquinolines for treating or inhibiting colonic polyps.
RU99123060A (ru) Замещенные 3-цианохинолины
RU2006106267A (ru) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
GEP20257770B (en) Compounds for the treatment of kinase-dependent disorders
KR100531969B1 (ko) 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법
FI4313981T3 (fi) 3,4-dihydro-2,7-naftyridiini-1,6(2h,7h)-dioneja mek-inhibiittoreina
AU2001245452A1 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
CO5150185A1 (es) N-[4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il- propoxi)-quinazolin-6-il]-acrilamida, un inhibidor irreversible de las cinasas de la tirosina
RU2002129353A (ru) Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств
RU2005113988A (ru) Стабилизированная фармацевтическая композиция, содержащая основные наполнители
JP2018511626A5 (https=)
MX338920B (es) Proceso para la preparacion de compuestos de aminocrotonilo.
RU2003114740A (ru) Азотсодержащие ароматические производные
Johnson Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib
RU2007134908A (ru) Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
RU2007115161A (ru) Новые производные фталазинона в качестве ингибиторов киназы аврора-а
JP2018513868A5 (https=)
RU2350618C2 (ru) ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
JP2014532063A5 (https=)
RU2005114487A (ru) Терапевтическое лечение
US20170252335A1 (en) Combination of Ceritinib with an EGFR Inhibitor
RU2004127869A (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов egfr-киназы
WO2005120504A3 (en) Cancer treatment method
JP2005529180A5 (https=)